Corneal Graft Rejection – Pipeline Review, 2019

The corneal graft rejection occurs when the donor cornea stimulates an immunogenic response to the acceptor patient. Corneal graft rejection is a prominent common reason for graft failure in the late post-surgery period. According to the Eye Bank Association of America, an estimated 82,000 corneal transplants were carried out in the U.S in the year 2016. The incidence rate of corneal transplant rejection is estimated to be between 2.0% -6.0%. It is very critical to diagnose graft reject with graft failure.

Current treatment of corneal graft rejection is determined by the damage to the corneal layer. The primary treatment of corneal transplant rejection usually involves 1% topical prednisolone acetate. Systemic therapy and oral prednisone are also administered for the treatment of corneal graft rejection.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for corneal graft rejection. For instance; OXB-202, which is being studied by Oxford Biomedica, is currently in phase-2 clinical trials for the study of safety, tolerability, and efficacy of OXB-202 patients with corneal graft rejection.

Presently most of the candidate for the corneal graft rejection treatment are in the preclinical phase of the study. Most of the studies for the discovery of novel therapeutics for corneal graft rejection are sponsored by industry.

Report Description

The report on ‘Corneal Graft Rejection – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for corneal graft rejection. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for corneal graft rejection.

The report on ‘Corneal Graft Rejection – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for corneal graft rejection
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for corneal graft rejection
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary